Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33530528 | 0.76 | PDK2 (0.41) | NPC1RAB9AGPR119NR1H2ESR2 | |
| SCHEMBL22462921 | 0.75 | MEN1 (0.54) | MEN1KMT2AGPR119STSUSP30 | |
| SCHEMBL33533406 | 0.74 | CYP11B2 (0.43) | GPR119NR1H2ESR2 | |
| SCHEMBL16422601 | 0.73 | MEN1 (0.67) | MEN1KMT2AGPR119USP30 | |
| SCHEMBL33532485 | 0.73 | CYP11B2 (0.41) | NR1H2ESR2 | |
| SCHEMBL27391167 | 0.72 | MEN1 (0.53) | MEN1KMT2AGPR119USP30 | |
| SCHEMBL25391302 | 0.71 | MEN1 (0.67) | MEN1KMT2ANPC1RAB9AGPR119 | |
| SCHEMBL18319317 | 0.71 | MEN1 (0.52) | MEN1KMT2AGPR119USP30 | |
| SCHEMBL2792425 | 0.71 | MEN1 (0.60) | MEN1KMT2AGPR119STSUSP30 | |
| SCHEMBL30878534 | 0.71 | ESR1 (0.58) | KMT2AESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | MEN1 3261/4885KMT2A 4018/4885NPC1 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.